

Allergy and rhinitis

Discover the connection


ImmunoCAP® blood tests help you rule in or rule out allergy and identify the allergens that add up to symptoms



Allergic rhinitis – A global burden and a diagnostic challenge




Allergic rhinitis is on the rise worldwide^{1,2}



Optimal patient management needs accurate diagnosis


But: Case history alone may not be sufficient

Nearly 2/3 of patients prescribed antihistamines for their reported allergic rhinitis have symptoms that are not due to allergy^{3,*}



*Study of 1-year managed care records among 4,643 patients who received one or more prescriptions for an oral antihistamine (loratadine, fexofenadine, or cetirizine).3

Similar symptoms – different causes and management⁴



The impact on patients' quality of life can be substantial

- Symptoms impact negatively on physical, social and psychological well-being.^{2,4,5}
- The effects of symptoms like sleep disturbance, daily fatigue and use of antihistamines can result in impaired school/work performance.^{2,4,5}
- Allergic rhinitis is a risk factor for the development of asthma.^{2,4,6}








Sensitization to more than one allergen complicates diagnosis and patient manage ment




In patients with allergic rhinitis poly-sensitization is common

- Up to 80% of allergic patients are sensitized to several allergen extracts.^{7,8}
- The average patient is sensitized to 3 allergens.^{7,8}



Sensitization to seasonal and perennial allergens add up to symptoms

Allergens can have cumulative effects, pushing the patient over the symptom threshold^{9,10}



Identifying the sensitizing allergens will help you outline a comprehensive avoidance plan to keep patient below symptom threshold.








ImmunoCAP can help to achieve a more accurate diagnosis



Add ImmunoCAP to your case history to improve diagnosis

Diagnostic certainty in ruling in or out allergy has been shown to increase when ImmunoCAP Complete Allergen results are added to clinical history^{11,12}



Guidelines recommend IgE testing, such as ImmunoCAP, in addition to clinical history and physical examination for patients with allergic rhinitis.¹³⁻¹⁵

Adequate allergy testing is he prerequisite for optimal care, including allergen avoidance, pharmacotherapy and immunotherapy.

EAACI (European Academy of Allergy and Clinical Immunology)¹³

Easy and safe testing for all kinds of patients

ImmunoCAP testing can be performed irrespective of:16-19

- Patient age (even in infants)
- Skin condition
- Medication
- Disease state
- · Pregnancy status

No need for precaution for severe reactions as with skin-prick test (SPT)^{16,20}







6

How to improve diagnostic certainty with ImmunoCAP



Regular

follow-up testing to

evaluate

changes

in allergy

profile

- 1 Request an ImmunoCAP test for the relevant allergens. Symptom profiles* help you identify the offending allergens.
- 2 Draw a blood sample. 80 µl whole blood (40 µl serum) for each allergen (capillary or a venous sample) and one extra 200 µl for the instrument.
- 3 Send the sample and request form to your local lab using ImmunoCAP.
- 4 Results come back

Wheeze/Rhinitis Child		Asthma/Rhinitis Adult	
g6 T	imothy	g6	Timothy
t3 E	Birch	t3	Birch
t25 A	sh	t25	Ash
w6 N	lugwort	w1	Ragweed
e1 (Cat	e1	Cat
e5 E	Dog	e5	Dog
d1 F	louse dust mite	d1	House dust mite
f1 E	gg white	w6	Mugwort
f2 C	Cow's milk	m6	Alternaria
f13 P	eanut	i6	Cockroach


^{*}Symptom profile containing relevant allergens. Local adaptation with respect to age and regional differences is recommended

Limitations of procedure - please refer to limitations contained in Directions for Use.

Confirmation of allergy and identification of causative allergens are crucial to correctly manage allergic diseases. Precise diagnosis allows the implementation of therapies oriented to the etiologic factors of allergic diseases, such as environmental measures and immunotherapy.

World Allergy Organization (WAO)¹⁵

ImmunoCAP helps identify the allergen(s) that add up to symptoms



^{*}Symptom profile containing relevant allergens. Local adaptation with respect to age and regional differences is recommended.





^{**}The IgE antibody level should be regarded as additional information helping the clinician confirm the clinical decision, based also on a case history and physical examination.

^{***}Factors to consider for a final diagnosis: age, degree of atopy, allergen load, type of sensitizing allergens, previous symptoms, other triggering factors.

The connection: Clinical history plus ImmunoCAP



Peter, 10 years old — case history:

- Peter, ten years old, visits his doctor due to perennial nasal obstruction and itchy and watery eyes.
- He says the symptoms have exacerbated during the spring.
- His mother explains that Peter suffered from mild eczema during infancy and he has a tendency to catch colds easily.

Diagnostic procedure

- Physical examination shows a slightly inflamed conjunctivae and pale blue nasal mucosa.
- The doctor suspects pollen allergy, infection and possibly non-specific nasal hyper responsiveness.



The patient described here is a fictitious example.

Peter's doctor orders ImmunoCAP Complete Allergen tests to get a better understanding of his allergy triggers

ImmunoCAP test results:							
	Allergen	sigE (kU _A /I)	Allergen	sigE (kU _A /I)			
g6	Timothy	<0.1	e5 Dog	<0.1			
t3	Birch	12.02	d1 House dust mite	8.43			
t25	Ash	<0.1	f1 Egg white	<0.1			
w6	Mugwort	<0.1	f2 Cow's milk	<0.1			
e1	Cat	7.23	f13 Peanut	<0.1			
Total IgE 149							

Interpretation and management

- Peter is diagnosed as allergic to birch, house dust mites and cats
- In order to push Peter below the symptom threshold, the doctor recommends that
 he limits his exposure to house dust mites by removing the carpet in his room and
 using allergen-protective bed covers.
- He is also recommended to not let the neighbour's cat into the house.
- An antihistamine is prescribed.
- During a follow up visit, Peter says he is experiencing fewer symptoms during pollen season and hardly ever needs to use his antihistamine.





10

Discover the connection with ImmunoCAP

Incorporate ImmunoCAP in your diagnostic process and help improve allergy management

- Find out if the symptoms are allergic or non-allergic^{11,12}
- Identify all the responsible allergens that push the patient over the symptom threshold¹⁰⁻¹²
- Develop an optimal management strategy to keep your patient below the symptom threshold¹³⁻¹⁵



References: 1. European Academy of Allergy and Clinical Immunology; Global Atlas of Allergic Rhinitis and Chronic Rhinosinusitis, 2015. 2. Bousquet J, et al. *Allergy*. 2008;63(Suppl 86):8-160. (ARIA Guideline). 3. Szeinbach SL, et al. *J Manag Care Pharm*. 2004;10(3):234-8. 4. Roberts G, et al. *Allergy*. 2013;68:1102-16. 5. Nathan RA. *Allergy Asthma Proc*. 2007;28:3-9. 6. NIH. Guidelines for the Diagnosis and Management of Asthma 2007. NIH Publication 08-4051. 7. Ciprandi G, et al. *Eur Ann Allergy Clin Immunol*. 2008;40(3):77-83. 8. Petersson CJ, et al. Sensitization profile in undiagnosed children with skin and respiratory allergy-like symptoms in primary care. Abstract presented at WAO, Buenos Aires, Argentina 6-10 December 2009. 9. Wickman M. *Allergy*. 2005;60(Suppl 79):14-18. 10. Burbach GJ, et al. *Allergy*. 2009;64:1507-15. 11. Adapted from Duran-Tauleria E, et al. *Allergy*. 2004;59(Suppl 78):35-41. 12. Adapted from Niggemann B, et al. *Pediatr Allergy Immunol*. 2013;24:195-209. 14. Seidman MD, et al. *Clinical Practice Guideline: Allergic Rhinitis. Otolaryngology - Head and Neck Surgery*. 2015;152(1S) S1-S43. 15. Pawankar R, et al. *World Allergy Organization (WAO) White Book on Allergy*, 2011. 16. Siles RI, et al. *Cleve Clin J Med*. 2011;78:585-92. 17. Bonnelykke K, et al. *J Allergy Clin Immunol*. 2008;121:646-51. 18. Belhocine W, et al. *Pediatr Allergy Immunol*. 2011;22:600-7. 19. Bacharier LB, et al. *Allergy*. 2003;58:921-8. 22. Sampson HA. *J Allergy Clin Immunol*. 2001;107:891-6.

thermoscientific.com/phadia

© 2015 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific Inc. and its subsidiaries. Manufacturer, Phadia AB, Uppsala Sweden.

Head office Sweden $+46\ 18\ 16\ 50\ 00$

Austria +43 1 270 20 20 **Belgium** +32 2 749 55 15 **Brazil** +55 11 2730 3134 **China** +86 800 810 5118

Czech Republic +420 220 518 743 Denmark +45 70 23 33 06 Finland +358 9 3291 0110 France +33 1 61 37 34 30 Germany +49 761 47 8050 Hong Kong +852 2885 4613 India +91 11 4610 7555/56 Italy +39 02 64 163 411

Japan +81 3 5826 1660 Korea +82 2 2027 5400 Norway +47 21 67 32 80 Portugal +351 21 423 5350 South Africa +27 11 792 6790 Spain +34 935 765 800 Sweden +46 18 16 60 60 Switzerland +41 43 343 4050 Taiwan +886 2 8751 6655 The Netherlands +31 30 602 37 00 United Kingdom/Ireland +44 1 908 769 110

USA +1 800 346 4364 **Other countries** +46 18 16 50 00

